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TonEBP is a DNA binding transcriptional enhancer that enables cellular adaptation to
hypertonic stress by promoting expression of specific genes. TonEBP expression is very
high in the renal medulla because local hypertonicity stimulates its expression. Given the
high level of expression, it is not well understood how TonEBP activity is modulated.
Here we report that TonEBP is post-translationally modified by SUMO, i.e., sumoylated,
in the renal medulla but not in other isotonic organs. The sumoylation is reproduced in
cultured cells when switched to hypertonicity. Analyses of site-directed TonEBP mutants
reveal that K556 and K603 are independently sumoylated in response to hypertonicity.
DNA binding is required for the sumoylation. Functional analyses of non-sumoylated
mutants and SUMO-conjugated constructs show that sumoylation inhibits TonEBP in a
dose-dependent manner but independent of the site of SUMO conjugation. Sumoylation
inhibits transactivation without affecting nuclear translocation or DNA binding. These data
suggest that sumoylation modulates the activity of TonEBP in the hypertonic renal medulla
to prevent excessive action of TonEBP.
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INTRODUCTION
TonEBP (tonicity-responsive enhancer binding protein), also
known as NFAT5 (nuclear factor of T cell 5), was originally
identified as the key transcription factor that enables the cellu-
lar survival under hypertonic conditions (Miyakawa et al., 1999).
TonEBP is a DNA binding protein that stimulates the transcrip-
tion of a variety of genes involved in the survival under hypertonic
conditions (Kwon et al., 2009). While some of these genes encode
proteins involved in organic osmolyte accumulation, how other
genes promote cellular adaptation to hypertonicity is poorly
understood (Lee et al., 2011). Animals deficient in TonEBP activ-
ity display severe renal atrophy which is preceded by massive
cell death in the renal medulla as cells fail to adapt to the local
hypertonicity (Lopez-Rodriguez et al., 2004).
TonEBP is activated by hypertonicity in multiple pathways—
nuclear translocation, enhanced transactivation, and increased
abundance. Tonicity-sensitive nuclear localization signal in the
TonEBP molecule is described for the hypertonicity-induced
nuclear translocation (Kwon et al., 2008). Although domains of
TonEBP involved in the hypertonicity stimulation are defined
(Lee et al., 2003), it remains unclear how tonicity regulates these
domains. Increased stability or half-life of TonEBP mRNA has
been described to explain the enhanced expression of TonEBP in
hypertonicity (Cai et al., 2005).
SUMO (small ubiquitin-like modifier) is structurally related
to ubiquitin. SUMO modification or sumoylation is an essential
post-translational modification that regulates protein functions
including transcription, signal transduction, and DNA repair
(Geiss-Friedlander and Melchior, 2007). In mammals, SUMO2
and SUMO3 are 97% identical to each other and about 50%
identical to SUMO1 (Saitoh and Hinchey, 2000).
In the kidney medulla, expression of TonEBP stays very high
due to local hypertonicity. Here we found evidence that the
TonEBP activity was modulated by sumoylation in the renal
medulla. TonEBP is sumoylated on two lysine residues in a man-
ner dependent on ambient hypertonicity. Sumoylation inhibits
the transactivation of TonEBP in a dose-dependent manner.
MATERIALS AND METHODS
ANIMAL STUDIES
Male Sprague-Dawley rats weight 180 g were purchased from
Harland Sprague Dawley Inc., Indianapolis, IN, USA. All the
procedures had been approved by the Institutional Animal Care
and Use Committee of the University of Maryland. The animals
were allowed to free access to water and food before they were
euthanized for collection of kidneys and urine samples.
CELL CULTURE AND TRANSFECTION
HEK293 cells were maintained in Dulbecco’s Minimum Essential
Medium (Invitrogen, Carlsbad, CA) supplemented with antibi-
otics and 10% fetal bovine serum (Invitrogen). Cells were trans-
fected using Lipofectamine2000 (Invitrogen). 0.25μg of plasmid
DNA in 250μl of Opti-MEM (Invitrogen) was mixed with 5μl of
Lipofectamine2000 dissolved in 250μl of Opti-MEM and incu-
bated at room temperature for 20min. The mixture was added
to a 1.5ml of trypsinized cell suspension containing 3.5 million
cells in antibiotics-free culture medium, and seeded in a well of
a 6-well cluster. After a day, the cells were cultured in isotonic
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or hyperosmotic medium made by addition of NaCl, sorbitol,
or urea.
DNA CONSTRUCTS
All the expression constructs were generated using standard
cloning procedures and verified by restriction mapping and
sequencing. A cDNA encoding the c-form of human TonEBP
mRNA (Maouyo et al., 2002) was cloned into a mammalian
expression vector pCMV-Tag2 to produce FLAG-tagged TonEBP.
Site-directed mutants were made using the QuickChange XL site-
directed mutagenesis kit (Stratagene, La Jolla, CA). SUMO fused
TonEBP constructs were made by insertion of PCR amplified
SUMO fragments (without the C-terminal di-glycine residues)
between FLAG and TonEBP. Expression plasmids for Ubc9,
Xpress-tagged SUMO isoforms, PIAS1, PIASxα were described
previously (Choi et al., 2006; Wei et al., 2006). Expression vec-
tors for mPIASy and mPIAS3 (Sramko et al., 2006) were kindly
provided by Juraj Bies (NIH, Bethesda).
IMMUNOBLOT AND IMMUNOPRECIPITATION
For immunoblot detection of sumoylated TonEBP, prevention
of proteolytic removal of SUMO was critical. Fresh rat tissues
including brain, kidney, and lung were immediately homogenized
for 30 s at full speed using Polytron (Brinkmann, Westbury, NY)
in 30 volumes of hot (90–95◦) lysis buffer (1.0% SDS, 1.0mM
sodium orthovanadate, and 10mM Tris-Cl, pH 7.4). An aliquot
was saved for protein assay using the BCA kit (Pierce, Rockford,
IL). Concentrated Laemmli buffer was mixed and boiled for
5min. As for HEK293 cells, washed and pelleted cells were
homogenized in the hot lysis buffer by passing through a 24-G
needle several times. TonEBP (Miyakawa et al., 1999) and FLAG
antibody (Sigma, St. Louis, MO) were used for immunoblot
analysis {1:2000}. For immunoprecipitation of TonEBP conju-
gated to the Xpress-tagged SUMO’s, transfected HEK293 cells
were homogenized in the hot lysis buffer and diluted 1:10 in
IP buffer [150mM NaCl, 1% Triton X-100, protease inhibitor
cocktail (Roche, Indianapolis, IN), 30mM Tris-Cl, pH 7.5]. The
diluted homogenate was incubated overnight with Xpress anti-
body (Invitrogen) at 4◦ and the antigen-antibody complex was
recovered using Protein G/A-agarose (Upstate, Billerica, MA).
LUCIFERASE ASSAY
To assay the TonE-driven transcription, 0.8 × 106 cells in sus-
pension were transfected with 50 ng of TonE-driven Photinus
luciferase expression construct (Colla et al., 2006) along with
100 ng of various combinations of empty vector plus TonEBP
expression vectors in a well of 24-well cluster. After 20 h, the
cells were switched to hypertonic medium or isotonic medium
and cultured for an additional 4 h. Activity of luciferase from
cell lysates was measured using a commercial kit, the Luciferase®
Reporter Assay system (Promega, Madisone, WI). To analyze the
transactivation of TonEBP, suspended cells were transfected with
200 ng of Gal4 upstream activation sequence-driven photinus
luciferase expression construct (pFR-Luc), 50 ng of expression
vector for GAL4-DBD (Gal4 DNA binding domain) fused to wild
type or mutant TonEBP. The cells were treated and expression of
luciferase was analyzed as above.
RNase PROTECTION ASSAY (RPA)
RNA was extracted from HEK293 cells using TriZol (Invitrogen).
RPA probes were synthesized using T7 or SP6 RNA polymerase
from the following cDNA’s cloned in pCRII-TOPO (Invitrogen):
human SMIT (nucleotides 1618–1967 of NM_006933)
and human AR (corresponding to nucleotides 608–992 of
NM_020299). The plasmid for synthesis of human β-actin probe
was purchased from Ambion (Austin, TX). A commercial kit
(Ambion) was used for RPA. Radioactivity of protected bands
was visualized and quantified using a phosphorImager (BioRad,
Hercules, CA). In each sample, the radioactivity of the SMIT or
AR mRNA band was corrected for RNA loading by dividing with
that of the β-actin mRNA band.
ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
Cell extracts were prepared from HEK293 cells transfected with
various TonEBP mutants using IP buffer (see above). Double-
stranded DNA containing “hTonE” sequence (Miyakawa et al.,
1999) was end-labeled using γ-[32P]-ATP. The cell extract (5μg
protein per reaction) was incubated for 10min with 1μg of
poly(dA·dT) in 20μl containing 20mMHEPES (pH 7.9), 50mM
KCl, 5mM MgCl2, 1mM dithiothreitol, and 5% (vol/vol) glyc-
erol. Where indicated 100 nM unlabeled hTonE was added. After
addition of 1 nM [32P]-hTonE, the reaction was incubated for
20min at room temperature. The mixture was electrophoresed
for 2.5 h on a 4% polyacrylamide gel in 45mM Tris, 45mM boric
FIGURE 1 | Slow TonEBP bands in the kidney and HEK293 cells
cultured in hypertonicity. (A) A representative TonEBP immunoblot of
brain, lung, and kidney inner medulla (Kid. IM) obtained from three
euhydrated rats. Urine osmolality was 1730 ± 60 mosmol/kg. (B) TonEBP
immunoblot of HEK293 cells cultured in isotonic (ISO) or hypertonic
medium (HYP) for 6 or 24 h. (C) TonEBP immunoblot of HEK293 cells
cultured in hyperosmotic medium containing additional 100mM NaCl
(NaCl), 200mM sorbitol (sorbitol), and 200mM urea (urea) for 6 h. TonEBP
and slow bands are indicated on the right. The slow bands are 16 and
32 kDa larger than the TonEBP band.
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acid, and 1mM EDTA at 150V. Radioactivity of the TonEBP
bands were visualized and quantified using PhosphorImager.
STATISTICAL ANALYSIS
Where indicated data are expressed in Mean and s.e.m. with the
number of independent experiments (n). T-test was performed
using Microsoft Excel software.
RESULTS
TonEBP IS DI-SUMOYLATED IN RESPONSE TO HYPERTONICITY
While performing immunoblot analysis of TonEBP in animal
tissues, we found that TonEBP was highly susceptible to pro-
teolysis. To minimize the proteolysis, we have adopted the use
of strong (1%) SDS in combination with immediate boiling for
sample preparation as described in Materials and Methods. The
new procedure yielded increased and reliable immunoblot sig-
nals for TonEBP. In addition, it came to our attention that two
slow bands emerged in addition to the normal TonEBP band
when samples from the outer (not shown) and inner medullae
(Figure 1A) of kidneys were used. The slow bands were not seen
in other tissues such as brain and lung (Figure 1A). Because the
renal medulla is hyperosmotic, we tested whether hyperosmo-
lality induced the slow TonEBP band. When HEK293 cells were
cultured in hyperosmotic medium made by addition of 100mM
NaCl, the slow bands appeared clearly after 4 h and increased
slowly over the course of 24 h (Figure 1B). The slow bands were
also observed in other cell lines such as MDCK, HepG2, MEF,
and RAW264.7 cells (data not shown). While NaCl or sorbitol
was effective, urea was not effective in inducing the slow bands
(Figure 1C) demonstrating that hypertonicity (effective hyper-
osmolality that causes water efflux from the cell) rather than
FIGURE 2 | TonEBP is sumoylated in response to hypertonicity. (A)
HEK293 cells were transfected with various combinations of TonEBP, Ubc9,
and Xpress-tagged SUMO1, SUMO2, or SUMO3, as indicated. After 20 h,
the cells were cultured for an additional 4 h in isotonic (I) or hypertonic
medium (H). Whole cell extracts (WCE) were prepared and immunoblotted
(IB) for TonEBP. Positions of TonEBP and slow TonEBP bands are indicated.
(B) Cells were transfected as above and WCE were immunoprecipitated
using anti-Xpression antibody. Immunoprecipitates (top) and WCE (bottom)
were immunoblotted for TonEBP. Positions of TonEBP and sumoylated
TonEBP (SUMO-TonEBP) bands are indicated at right.
hyperosmolality per se was the signal for the induction of the slow
bands.
Since the slow TonEBP bands were ∼16 and ∼32 kDa larger
than TonEBP, we asked whether they were TonEBP molecules
conjugated to SUMO, i.e., sumoylated TonEBP molecules.
We found that overexpression of Ubc9, the only known E2
ligase for SUMO, promoted the formation of slow bands
from endogenous TonEBP or transfected TonEBP (not shown;
longer exposure the immunblot shown in Figure 2A revealed
the slow bands in the first six lanes). Simultaneous over-
expression of TonEBP, Ubc9, and Xpress-tagged SUMO iso-
forms resulted in a dramatic enhancement of the slow bands
(Figure 2A). When the transfected cells were immunoprecipi-
tated using antibodies against the Xpress tag, the slow bands
were found in the pellets with TonEBP immuno-reactivity
(Figure 2B) directly demonstrating that the slow bands were
indeed sumoylated TonEBP molecules. The data in Figure 2
showed that SUMO3 and SUMO2 were far more efficient in
sumoylation of TonEBP, and the sumoylation was stimulated by
hypertonicity.
FIGURE 3 | TonEBP is sumoylated on lysines 556 and 603. (A) Positions
of lysine residues that fit the consensus sequence for sumoylation (KxE:
 is a large hydrophobic residue; x is any residue) on a schematic primary
structure of TonEBP. Rel homology domain (RHD), three activation domains
(AD), and two modulation domains (MD) are shown. (B) HEK293 cells were
transfected with wild type TonEBP (WT) or each of the TonEBP mutants
shown along with SUMO3 and Ubc9. The cells were cultured for 4 h in
hypertonic medium before immunoblot detection of TonEBP. Positions of
TonEBP and sumoylated TonEBP (SUMO-TonEBP) are indicated. (C)
HEK293 cells were co-transfected with a TonE-driven luciferase reporter
plus empty expression plasmid (Vector) or expression plasmid containing
WT or each of the TonEBP mutants as indicated. The cells were cultured for
4 h in isotonic (ISO) or hypertonic (HYP) medium before analysis of
luciferase. Expression of luciferase activity is shown relative to isotonic
vector control. K556R or K603R is significantly different from WT or
K(556/603) both in ISO and HYP: p < 0.01. Mean + s.e.m., n = 6.
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The majority of lysine residues conjugated to SUMO fit the
consensus sequence: KxE ( is a large hydrophobic residue
and x is any residue). There are six lysines in the human
TonEBP molecule that fit the consensus as shown in Figure 3A.
When individually mutated to arginine residues, only K556R and
K603R mutants showed one slow bands while other mutants
displayed two slow bands. When both residues were mutated
(K556R/K603R), the remaining slow band disappeared demon-
strating that TonEBP were di-sumoylated on K556 and K603. The
activity of TonEBP increased in the single mutant and even higher
in the double mutant (Figure 3C) suggesting that sumoylation
inhibits TonEBP in a manner dependent on the stoichiometry of
sumoylation (see more below). In addition, we concluded that
sumoylations on the two lysine residues were independent of
each other because mutation of one site did not affect sumoy-
lation of the other. The sequence around K556 and K603 is
conserved in all species from human to zebrafish suggesting
that sumoylation of TonEBP is an important aspect of TonEBP
regulation.
MECHANISM OF HYPERTONICITY-INDUCED SUMOYLATION
Recent studies have shown that phosphorylation is required for
sumolyation in several transcription factors such as heat-shock
factors, GATA-1, and myocyte enhancer factor two (Gregoire
and Yang, 2005; Hietakangas et al., 2006). This is mediated by
the phsophorylation-dependent sumoylation motif: KxExxSP.
The sequences around the two sumoylation sites of TonEBP
appear to conform to the consensus: VK556KEISS601P and
IK603SEDVT608P. Since TonEBP is phosphorylated in response
to hypertonicity (Dahl et al., 2001; Lee et al., 2002), we exam-
ined the role of S600/S601 and T608. For this, we made
FIGURE 4 | DNA binding is required for sumoylation of TonEBP. (A)
HEK293 cells were transfected with empty vector (Vec) or one the
following FLAG-tagged constructs: WT, wild type; DIM (dimer interface
mutant), F464A/I466A; DBM (DNA binding mutant), T298A/E299A/R302A.
Top: Cell lysates were immunoblotted for FLAG. Bottom: EMSA was
performed using the cell lysates and 1 nM of [32P]-TonE. Positions of
FLAG-TonEBP and DNA bound TonEBP are indicated. (B) HEK293 cells
were transfected with Ubc9, SUMO3, and each of the constructs shown in
(A) and MT (K556R/K603R mutant, see Figure 3). The cells were cultured
for 4 h in hypertonic medium and immunoblotted for TonEBP.
phosphorylation-negative mutants—S600A/S601A and T608A—
as well and phosphorylation-mimicking mutants S601D and
T608E. However, sumoylation and transcriptional activity of
these mutants were not affected by any of the mutations
FIGURE 5 | Effects of sumoylation on the transcriptional activity of
TonEBP. (A) Schematics of FLAG-tagged TonEBP constructs are shown at
bottom: wild type TonEBP (WT), SUMO3-fused TonEBP (SUMO-WT),
K556R/K603R mutant TonEBP (MT), or SUMO3-fused MT (SUMO-MT).
These constructs were transfected into HEK293 cells and immunoblotted
for FLAG (top). (B) HEK293 cells were transfected with empty vector or
increasing amounts of the constructs shown in A along with a TonE-driven
luciferase reporter, and cultured for 4 h in isotonic (ISO) or hypertonic
medium (HYP). Expression of luciferase activity is show as in Figure 3. (C)
HEK293 cells were transfected with empty vector or each of the constructs
shown in (A). The cells were cultured for 6 h in isotonic (ISO) or hypertonic
(HYP) medium. SMIT and β-actin mRNA’s were measured by RPA. The
radioactivity in each SMIT band was divided by that of corresponding β-actin
band to correct for RNA loading. In ISO, WT was significantly different from
SUMO-WT (p < 0.01) but not from SUMO-MT. Mean + s.e.m., n = 3.
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individually or in combination (data not shown). We conclude
that phosphorylation of S600/S601 or T608 has no bearings on
the sumoylation of TonEBP.
Like NFκB, TonEBP forms a dimer and the dimerization
is required for DNA binding (Lee et al., 2002; Stroud et al.,
2002). We made site-directed mutants incapable of dimer-
ization (DIM—dimer interface mutant: F464A/I466A) and
incapable of DNA contact (DBM—DNA binding mutant:
T298A/E299A/R302A). Coimmunoprecipitation analysis
revealed that DIM was monomeric in solution while WT formed
dimers (data not shown). As expected from the crystal structure
of the Rel-homology domain of TonEBP (Stroud et al., 2002),
DIM as well as DBM failed to bind DNA (Figure 4A). It should
be pointed out that the sumoylation-negative mutant (MT in
Figure 4B) bound DNA normally (see below). Interestingly,
sumoylation was dramatically reduced in DIM and DBM as
in MT (Figure 4B). These data provide evidence that DNA
binding is required for the sumoylation of TonEBP. This raises
the possibility that sumoylation of TonEBP takes place on the
surface of chromatin when TonEBP is bound to DNA.
SUMOYLATION INHIBITS TonEBP
The data shown in Figure 3C indicate that sumoylation leads to
inhibition of TonEBP. To explore the functional consequence of
the sumoylation further, we examined transcriptional activity of
several TonEBP mutants along with WT (wild type TonEBP):
SUMO-WT (SUMO3 was fused to WT to mimic sumoylated
TonEBP), MT (K556R/K603Rmutant that is incapable of sumoy-
lation as shown in Figure 3), and SUMO-MT (MT fused to
SUMO3) as schematically depicted in Figure 5A. WT stimu-
lated the expression of TonE-driven reporter in a dose dependant
manner in isotonic and hypertonic condition, as reported pre-
viously (Maouyo et al., 2002). SUMO-WT is practically inactive
except for a small activity in isotonicity, while MT was two times
more active than WT. Interestingly SUMO-MT displayed activ-
ity comparable to that of WT suggesting that WT was normally
mono-sumoylated. Essentially the same effects were observed on
the mRNA expression of TonEBP target genes, SMIT (Figure 5C)
and AR (not shown), especially under isotonic conditions. Taken
together, the data in Figure 5 demonstrate that sumoylation
inhibits TonEBP in a manner dependent on the stoichiometry of
sumoylation.
The data in Figure 2 showed that the efficiency of TonEBP
sumoylation differed depending on the isoform of SUMO—
SUMO1, SUMO2, and SUMO3—involved. Here we examined
the different isoforms of SUMO on the efficiency of TonEBP inhi-
bition. We made more SUMO fusion constructs using SUMO1
and SUMO2 in addition to SUMO3 as depicted in Figure 6A.
While the conjugation of SUMO2 led to almost identical results
to that of SUMO3, the conjugation of SUMO1 resulted in a
smaller inhibition of TonEBP (Figure 6B). This is not surprising
because SUMO2 and SUMO3 share 97% of amino acids while
SUMO1 shares only 50% with SUMO2 or SUMO3 (Saitoh and
Hinchey, 2000). Combined with the data in Figure 2, these results
FIGURE 7 | Effects of sumoylation on DNA binding of TonEBP. Top:
HEK293 cells were transfected with the constructs shown in Figure 4A.
Cell lysates were prepared and immunoblotted for FLAG. Bottom: EMSA
was performed on the cell lysates using 1 nM [32P]-labeled DNA containing
TonE in the absence or presence of 100 nM unlabeled DNA containing TonE
as indicated (Bottom). DNA bound TonEBP is indicated.
FIGURE 6 | SUMO isoform-dependent effects of sumoylation on the transcriptional activity of TonEBP. (A) Schematics and expression of constructs are shown as
in Figure 5A, except that SUMO1, SUMO2, and SUMO3 were used to make fusion proteins. (B) HEK293 cells were transfected and analyzed as in Figure 5B.
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show that SUMO2 and SUMO3 are more effective in inhibiting
TonEBP compared to SUMO1 as well as being more efficient in
the sumoylation of TonEBP.
TRANSACTIVATION OF TonEBP IS INHIBITED BY SUMOYLATION
We asked how sumoylation inhibited TonEBP using the non-
sumoylated and sumoylation-mimicking TonEBP mutants dis-
cussed above. First, we examined the nuclear translocation
of TonEBP in response to hypertonicity. We found that all
the mutants displayed normal nuclear translocation (data not
shown). Second, we found that the mutants bound TonE con-
taining DNA like wild type TonEBP with comparable efficiency
and affinity (Figure 7). Thus, sumoylation of TonEBP did not
influence the nuclear translocation or DNA binding.
Next, we examined the transactivation of TonEBP by employ-
ing fusion with the Gal4 DNA binding domain (G4DBD). To
eliminate potential complications of dimer formation by TonEBP,
dimer interface mutations (see Figure 4) were introduced into
TonEBP as indicated in Figure 8A. We later found that introduc-
tion of these mutations did not affect the results, i.e., the results
were the same without or with the dimer interface mutations
(not shown). As shown in Figure 8B, wild type TonEBP displayed
a strong transactivation, which was stimulated by hypertonic-
ity as reported earlier (Lee et al., 2003). The transactivation was
inhibited more than 80% by SUMO fusion (G4DBD-SUMO-
WTDIM), but stimulated by several folds in the mutant incapable
of being sumoylated (G4DBD-MTDIM). These data demonstrate
that sumoylation is a powerful negative regulator for the transac-
tivation of TonEBP.
DISCUSSION
In order to understand the slow TonEBP immunoreactive bands
observed in the renal medulla, we investigated sumoylation of
TonEBP. The slow bands are not observed in isotonic tissues like
brain and lung. On the other hand, the slow bands are reproduced
in cultured cells when the cells are subjected to hypertonicity.
Because of the transient nature of sumoylation in general, we used
overexpression of SUMO E2 ligase Ubc9 in combination with
SUMO isoforms to demonstrate that TonEBP is di-sumolyated
on lysine 556 and lysine 603. The sumoylation appears to take
place in the nucleus because DNA binding is required. This is
supported by the time course of sumoylation in response to
FIGURE 8 | Effects of sumoylation on the transactivation of TonEBP.
(A) Left: The DNA binding domain of Gal4 (G4DBD) was fused to the
TonEBP constructs shown in Figure 5 except that F464A/I466A
mutations (indicated by “DIM”) were introduced to prevent dimer
formation. Right: The constructs were individually transfected into
HEK293 cells and immunoblotted for G4DBD. (B) HEK293 cells were
transfected with each of the constructs shown in (A) along with a
Gal4-luciferase reporter. The cells were cultured for 4 h in isotonic (ISO)
or hypertonic (HYP) medium before analysis of luciferase. Expression of
luciferase activity is shown relative to isotonic vector control. Values in
all the constructs are different from each other both in ISO and HYP
(p < 0.01). Mean + s.e.m., n = 3.
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hypertonicity which mirrors the previously reported time course
of binding to the TonE sites (Miyakawa et al., 1998). Studies
using site-directed TonEBP mutants incapable of sumoylation
and SUMO-conjugated TonEBP constructs reveal that TonEBP is
inhibited by sumoylation in a dose-dependent manner regardless
of the position of SUMO conjugation on the TonEBP molecule.
Sumoylation inhibits TonEBP by reducing its transactivation
without affecting nuclear translocation or DNA binding. From
these data we can envision the following scheme of events after
a cell is exposed to hypertonicity. Initially the nuclear TonEBP
abundance rises due to enhanced expression in combination with
nuclear translocation leading to DNA binding and expression of
TonEBP target genes. Later, the TonEBPmolecules bound to DNA
are sumoylated and their transactivation decreases. Such temper-
ing of TonEBP activity might be important for homeostasis in
the renal medulla where TonEBP expression is very high most
of the time. It was reported previously that the high concentra-
tion of nitric oxide in the renal medulla also inhibits TonEBP
by direct S-nitrosylation (Neuhofer et al., 2009). Thus, the high
level of TonEBP expression in the renal medulla is counterbal-
anced by inhibitory post-translational modifications including
sumoylation and S-nitrosylation.
In many other transcription factors whose transactivation is
inhibited by sumoylation, the underlying mechanism involves
recruitment of histone deacetylases (HDAC’s) and interaction
with co-repressors (Gill, 2005). Indeed, we found that TonEBP
was co-immunoprecipitated with HDAC1 (data not shown).
However, the interaction was intact in non-sumoylated and
SUMO-fusion constructs suggesting that sumoylation did not
lead to recruitment of HDAC1. In addition an inhibitor of
HDAC1, trichostatin A, did not affect the transactivation of non-
sumoylated and sumoylation-mimicking mutants (not shown). It
appears that the inhibition of transactivation by sumoylation is
mediated by factors other than deacetylation.
ACKNOWLEDGMENT
This work was supported by the National Research Foundation of
Korea (No 20110020163).
REFERENCES
Cai, Q., Ferraris, J. D., and Burg, M. B. (2005). High NaCl increases
TonEBP/OREBP mRNA and protein by stabilizing its mRNA. Am. J. Physiol.
Renal. Physiol. 289, E803–E807. doi: 10.1152/ajprenal.00448.2004
Choi, S. J., Chung, S. S., Rho, E. J., Lee, H. W., Lee, M. H., Choi, H. S., et al. (2006).
Negative modulation of RXRalpha transcriptional activity by small ubiquitin-
related modifier (SUMO) modification and its reversal by SUMO-specific
protease SUSP1. J. Biol. Chem. 281, 30669–30677. doi: 10.1074/jbc.M6040
33200
Colla, E., Lee, S. D., Sheen, M. R., Woo, S. K., and Kwon, H. M. (2006). TonEBP is
inhibited by RNA helicase A via interaction involving the E’F loop. Biochem. J.
393, 411–419. doi: 10.1042/BJ20051082
Dahl, S. C., Handler, J. S., and Kwon, H. M. (2001). Hypertonicity-induced phos-
phorylation and nuclear localization of the transcription factor TonEBP. Am. J.
Physiol. Renal. Physiol. 280, C248–C253.
Geiss-Friedlander, R., and Melchior, F. (2007). Concepts in sumoylation: a decade
on. Nat. Rev. Mol. Cell Biol. 8, 947–956. doi: 10.1038/nrm2293
Gill, G. (2005). Something about SUMO inhibits transcription. Curr. Opin. Genet.
Dev. 15, 536–541. doi: 10.1016/j.gde.2005.07.004
Gregoire, S., and Yang, X. J. (2005). Association with class IIa histone deacetylases
upregulates the sumoylation of MEF2 transcription factors. Mol. Cell. Biol. 25,
2273–2287. doi: 10.1128/MCB.25.6.2273-2287.2005
Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M., Palvimo, J. J., Nakai, A.,
et al. (2006). PDMS, a motif for phosphorylation-dependent SUMO modifica-
tion. Proc. Natl. Acad. Sci. U.S.A. 103, 45–50. doi: 10.1073/pnas.0503698102
Kwon, M. S., Lee, S. D., Kim, J. A., Colla, E., Choi, Y. J., Suh, P. G., et al. (2008).
Novel nuclear localization signal regulated by ambient tonicity in vertebrates.
J. Biol. Chem. 283, 22400–22409. doi: 10.1074/jbc.M710550200
Kwon, M. S., Na, K. Y., Moeckel, G., Lee, S. D., and Kwon, H. M. (2009). Urea
promotes TonEBP expression and cellular adaption in extreme hypertonicity.
Pflgers Arch. 459, 183–189. doi: 10.1007/s00424-009-0696-5
Lee, S. D., Choi, S. Y., Lim, S. W., Lamitina, S. T., Ho, S. N., Go, W. Y.,
et al. (2011). TonEBP stimulates multiple cellular pathways for adaptation
to hypertonic stress: organic osmolyte-dependent and–independent path-
ways. Am. J. Physiol. Renal. Physiol. 300, F707–F715. doi: 10.1152/ajprenal.002
27.2010
Lee, S. D., Colla, E., Sheen, M. R., Na, K. Y., and Kwon, H. M. (2003). Multiple
domains of TonEBP cooperate to stimulate transcription in response to hyper-
tonicity. J. Biol. Chem. 278, 47571–47577. doi: 10.1074/jbc.M308795200
Lee, S. D., Woo, S. K., and Kwon, H. M. (2002). Dimerization is required for
phosphorylation and DNA binding of TonEBP/NFAT5. Biochem. Biophys. Res.
Commun. 294, 968–975. doi: 10.1016/S0006-291X(02)00572-7
Lopez-Rodriguez, C., Antos, C. L., Shelton, J. M., Richardson, J. A., Lin, F.,
Novobrantseva, T. I., et al. (2004). Loss of NFAT5 results in renal astrophy and
lack of tonicity-responsive gene expression. Proc. Natl. Acad. Sci. U.S.A. 101,
2392–2397. doi: 10.1073/pnas.0308703100
Maouyo, D., Kim, J. Y., Lee, S. D., Wu, Y., Woo, S. K., and Kwon, H. M.
(2002).Mouse TonEBP-NFAT5: expression in early development and alternative
splicing. Am. J. Physiol. Renal. Physiol. 282, F802–F809. doi: 10.1152/ajpre-
nal.00123.2001
Miyakawa, H., Woo, S. K., Chen, C., Dahl, S. C., Handler, J. S., and Kwon,
H. M. (1998). Cis- and trans-acting factors regulating transcription of the
BGT1 gene in response to hypertonicity. Am. J. Physiol. Renal. Physiol. 274,
F753–F761.
Miyakawa, H., Woo, S. K., Dahl, S. C., Handler, J. S., and Kwon, H. M. (1999).
Tonicity-responsive enhancer binding protein, a rel-like protein that stimu-
lates transcription in response to hypertonicity. Proc. Natl. Acad. Sci. U.S.A. 96,
2538–2542. doi: 10.1073/pnas.96.5.2538
Neuhofer,W., Fraek,M. L., and Beck, F. X. (2009). Nitric oxide decreases expression
of osmoprotective genes via direct inhibition of TonEBP transcriptional activity.
Pflgers Arch. 457, 831–843. doi: 10.1007/s00424-008-0540-3
Saitoh, H., and Hinchey, J. (2000). Functional heterogeneity of small ubiquitin-
related protein modifier SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275,
6252–6258. doi: 10.1074/jbc.275.9.6252
Sramko, M., Markus, J., Kabat, J., Wolff, L., and Bies, J. (2006). Stress-induced inac-
tivation of the c-Myb transcription factor through conjugation of SUMO-2/3
proteins. J. Biol. Chem. 281, 40065–40075. doi: 10.1074/jbc.M609404200
Stroud, J. C., Lopez-Rodriguez, C., Rao, A., and Chen, L. (2002). Structure of a
TonEBP-DNA complex reveals DNA enriched by a transcription factor. Nat.
Struct. Biol. 9, 90–94. doi: 10.1038/nsb749
Wei, H., Wang, X., Gan, B., Urvalek, A. M., Melkoumian, Z. K., Guan, J. L.,
et al. (2006). Sumoylation delimits KLF8 transcriptional activity associ-
ated with the cell cycle regulation. J. Biol. Chem. 281, 16664–16671. doi:
10.1074/jbc.M513135200
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 19 March 2014; accepted: 09 May 2014; published online: 19 June 2014.
Citation: Kim J-A, Kwon MJ, Lee-Kwon W, Choi SY, Sanada S and Kwon HM (2014)
Modulation of TonEBP activity by SUMO modification in response to hypertonicity.
Front. Physiol. 5:200. doi: 10.3389/fphys.2014.00200
This article was submitted to Integrative Physiology, a section of the journal Frontiers
in Physiology.
Copyright © 2014 Kim, Kwon, Lee-Kwon, Choi, Sanada and Kwon. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org June 2014 | Volume 5 | Article 200 | 7
